

# Robert Zeillinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/847708/publications.pdf>

Version: 2024-02-01

220  
papers

8,564  
citations

38742

50  
h-index

69250

77  
g-index

222  
all docs

222  
docs citations

222  
times ranked

11988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues. <i>Scientific Reports</i> , 2015, 5, 8057.	3.3	653
2	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. <i>Acta Oncologica</i> , 2011, 50, 700-710.	1.8	213
3	Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain.. <i>Genome Research</i> , 1995, 4, 234-238.	5.5	184
4	Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 710-714.	7.0	174
5	Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. , 1996, 69, 247-253.		158
6	Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer. <i>Molecular Cancer Research</i> , 2005, 3, 335-343.	3.4	133
7	Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. , 1997, 74, 455-458.		132
8	Transdominant p53 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo. <i>Cancer Research</i> , 2004, 64, 2449-2460.	0.9	129
9	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 512-517.	1.4	124
10	Expression of KLF5 is a Prognostic Factor for Disease-Free Survival and Overall Survival in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 2442-2448.	7.0	108
11	A prognostic gene expression index in ovarian cancer – validation across different independent data sets. <i>Journal of Pathology</i> , 2009, 218, 273-280.	4.5	107
12	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 15-21.	1.4	107
13	Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma. <i>Cancer</i> , 2005, 104, 2417-2429.	4.1	105
14	Interleukin-1 and Interleukin-6 Gene Polymorphisms and the Risk of Breast Cancer in Caucasian Women: Table 1.. <i>Clinical Cancer Research</i> , 2005, 11, 5718-5721.	7.0	103
15	Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 898-901.	7.0	99
16	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma – Analysis of patient data in the prospective OVCAD study. <i>Gynecologic Oncology</i> , 2013, 131, 15-20.	1.4	99
17	Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. <i>BMC Cancer</i> , 2010, 10, 666.	2.6	96
18	Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IV: Analysis of the OVCAD Data. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 380-385.	2.5	91

#	ARTICLE	IF	CITATIONS
19	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. <i>Clinical Cancer Research</i> , 2005, 11, 8372-8383.	7.0	89
20	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	1.6	87
21	The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 333-342.	2.5	86
22	Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 42-48.	2.8	85
23	KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. <i>BMC Cancer</i> , 2009, 9, 111.	2.6	80
24	Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. <i>Breast Cancer Research and Treatment</i> , 2002, 71, 249-255.	2.5	77
25	Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: Relevance for paclitaxel transport. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 417-426.	5.6	73
26	Small cell lung cancer: model of circulating tumor cell tumorspheres in chemoresistance. <i>Scientific Reports</i> , 2017, 7, 5337.	3.3	73
27	Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer. <i>Oncology</i> , 1997, 54, 475-481.	1.9	72
28	Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. <i>Human Reproduction</i> , 2001, 16, 1644-1647.	0.9	72
29	CXCR4 is Expressed in Ductal Carcinoma in situ of the Breast and in Atypical Ductal Hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 247-250.	2.5	72
30	Alternative splicing of p53 and p73: the novel p53 splice variant p53 <sup>Δ1</sup> is an independent prognostic marker in ovarian cancer. <i>Oncogene</i> , 2010, 29, 1997-2004.	5.9	72
31	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	6.4	72
32	An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. <i>Cancer Research</i> , 2003, 63, 3066-8.	0.9	71
33	In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. <i>British Journal of Cancer</i> , 2007, 96, 485-491.	6.4	68
34	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.9	68
35	Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. <i>Cancer Research</i> , 2007, 67, 11876-11885.	0.9	67
36	Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: Proof of concept. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 100-111.	1.5	67

#	ARTICLE	IF	CITATIONS
37	Patterns of allele losses suggest the existence of five distinct regions of loh on chromosome 17 in breast cancer. <i>International Journal of Cancer</i> , 1994, 56, 193-199.	5.1	66
38	DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. <i>British Journal of Cancer</i> , 1996, 74, 1984-1989.	6.4	65
39	Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2253-9.	7.0	65
40	A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 850-860.	4.1	63
41	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. <i>Oncotarget</i> , 2014, 5, 462-472.	1.8	63
42	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. <i>British Journal of Cancer</i> , 1998, 77, 1870-1874.	6.4	61
43	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF- $\kappa$ B activation. <i>Annals of Oncology</i> , 2012, 23, 1795-1802.	1.2	60
44	Circulating Cell-Free DNA in Plasma of Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation: A Potential Diagnostic Tool for Therapy Monitoring. <i>Disease Markers</i> , 2008, 25, 159-165.	1.3	59
45	Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the <sc>OVCAD</sc> Consortium. <i>Cancer Science</i> , 2012, 103, 1334-1341.	3.9	59
46	Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 422.	2.6	59
47	ABC transporter gene expression in benign and malignant ovarian tissue. <i>Gynecologic Oncology</i> , 2010, 117, 198-201.	1.4	58
48	Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. <i>Gynecologic Oncology</i> , 2013, 128, 245-251.	1.4	56
49	Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer. , 1998, 22, 186-199.		55
50	Expression Profiling of Mammary Carcinoma Cell Lines: Correlation of in vitro Invasiveness with Expression of CD24. <i>Tumor Biology</i> , 2002, 23, 139-145.	1.8	55
51	Perturbation of the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5. <i>Clinical Cancer Research</i> , 2005, 11, 8585-8591.	7.0	54
52	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53
53	Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Ovarian Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 134-137.	1.4	51
54	Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. <i>Cell Adhesion and Migration</i> , 2016, 10, 360-367.	2.7	50

#	ARTICLE	IF	CITATIONS
55	Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 205-207.	2.5	48
56	Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 91-97.	2.5	48
57	Methylation status of <i>TUSC3</i> is a prognostic factor in ovarian cancer. <i>Cancer</i> , 2013, 119, 946-954.	4.1	48
58	Polymorphisms of the angiotensinogen gene, the endothelial nitric oxide synthase gene, and the interleukin-1beta gene promoter in women with idiopathic recurrent miscarriage. <i>Molecular Human Reproduction</i> , 2002, 8, 95-100.	2.8	47
59	Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 37-46.	2.5	46
60	Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods. <i>Cancer Letters</i> , 2010, 293, 117-123.	7.2	46
61	The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-13.	2.5	46
62	Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 268-275.	2.5	46
63	Genetic Polymorphisms Associated With Thrombophilia and Vascular Disease in Women With Unexplained Late Intrauterine Fetal Death: A Multicenter Study. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 42-44.	1.7	45
64	Circulating Tumor Cells in Small Cell Lung Cancer: Ex Vivo Expansion. <i>Lung</i> , 2015, 193, 451-452.	3.3	45
65	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64.	2.8	45
66	Fetal fibronectin as a selection criterion for induction of term labor. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 1513-1517.	1.3	44
67	Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. <i>Oncotarget</i> , 2015, 6, 17261-17275.	1.8	44
68	Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. <i>British Journal of Cancer</i> , 1995, 71, 1292-1296.	6.4	43
69	BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF- $\beta$ treatment. <i>Gynecologic Oncology</i> , 2010, 117, 189-197.	1.4	43
70	Association of myeloperoxidase with ovarian cancer. <i>Tumor Biology</i> , 2014, 35, 141-148.	1.8	43
71	Expression of MUC1 splice variants in benign and malignant ovarian tumours. <i>International Journal of Cancer</i> , 2002, 100, 166-171.	5.1	42
72	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	1.8	42

#	ARTICLE	IF	CITATIONS
73	Fetal fibronectin as a marker to predict the onset of term labor and delivery. American Journal of Obstetrics and Gynecology, 1995, 172, 134-137.	1.3	41
74	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. Journal of Ovarian Research, 2013, 6, 42.	3.0	41
75	Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. International Journal of Cancer, 2001, 95, 394-397.	5.1	40
76	Î”133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. British Journal of Cancer, 2011, 105, 1593-1599.	6.4	40
77	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncology Reports, 2005, 13, 375-87.	2.6	39
78	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	1.4	38
79	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. Oncology Reports, 2003, 10, 1025-9.	2.6	38
80	A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertility and Sterility, 2004, 81, 1638-1641.	1.0	37
81	Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization. Journal of Molecular Diagnostics, 2009, 11, 508-513.	2.8	37
82	hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. Clinical Cancer Research, 2011, 17, 7816-7827.	7.0	37
83	EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Disease Markers, 2017, 2017, 1-9.	1.3	37
84	Identification of Genes Associated with the Invasive Status of Human Mammary Carcinoma Cell Lines by Transcriptional Profiling. Tumor Biology, 2003, 24, 189-198.	1.8	36
85	Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertility and Sterility, 2006, 85, 462-467.	1.0	36
86	Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Research and Treatment, 2006, 98, 151-155.	2.5	36
87	The N-Terminally Truncated p53 Isoform Î”40p53 Influences Prognosis in Mucinous Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 372-379.	2.5	36
88	Tumor necrosis factor-Î± promoter polymorphisms and endometriosis. Journal of the Society for Gynecologic Investigation, 2002, 9, 313-318.	1.7	36
89	High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genetics and Cytogenetics, 2001, 129, 23-29.	1.0	35
90	Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecologic Oncology, 2004, 93, 686-690.	1.4	35

#	ARTICLE	IF	CITATIONS
91	Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. <i>Molecular Cancer</i> , 2012, 11, 69.	19.2	35
92	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018, 9, 812-823.	1.8	35
93	BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization. <i>Clinical Chemistry</i> , 1999, 45, 976-981.	3.2	34
94	Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. <i>Cancer Letters</i> , 1998, 130, 69-76.	7.2	33
95	p53-dependent radioresistance in ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2000, 150, 191-199.	7.2	33
96	Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. <i>Anticancer Research</i> , 2010, 30, 1341-5.	1.1	33
97	Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2011, 121, 537-541.	1.4	32
98	Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. <i>Oncology Reports</i> , 2011, 26, 1037-45.	2.6	31
99	Quantitative Determination of Gene Expression by Competitive Reverse Transcriptionâ€“Polymerase Chain Reaction in Degraded RNA Samples. <i>Analytical Biochemistry</i> , 1997, 251, 173-177.	2.4	30
100	The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. <i>Gynecologic Oncology</i> , 2005, 98, 211-216.	1.4	30
101	Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. <i>International Journal of Oncology</i> , 2013, 42, 1383-1389.	3.3	30
102	Novel MUC1 Splice Variants Are Expressed in Cervical Carcinoma. <i>Gynecologic Oncology</i> , 2001, 83, 343-347.	1.4	29
103	Human Progesterone Receptor Gene Polymorphism PROGINS and Risk for Breast Cancer in Austrian Women. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 131-137.	2.5	29
104	Fibroblast growth factor receptor 4 gene ( <i>FGFR4</i> ) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012, 131, E586-91.	5.1	29
105	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 178.	2.6	29
106	Expression of mucins and cytokeratins in ovarian cancer cell lines. <i>Cancer Letters</i> , 1999, 145, 133-141.	7.2	28
107	p16INK4a Expression in Invasive Vulvar Squamous Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 279-283.	1.2	28
108	Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2002, 185, 79-85.	7.2	27



#	ARTICLE	IF	CITATIONS
109	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. <i>International Journal of Oncology</i> , 2003, 22, 1117.	3.3	26
110	Vascular endothelial growth factor gene polymorphisms in ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 105, 385-389.	1.4	26
111	Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer. <i>Cells</i> , 2019, 8, 880.	4.1	26
112	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> , 2003, 10, 405-10.	2.6	26
113	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 506-510.	1.4	25
114	Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (<65) and elderly (≥65) patients. <i>European Journal of Cancer</i> , 2012, 48, 2962-2968.	2.8	25
115	Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4047-4054.	1.8	25
116	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. <i>Cancers</i> , 2022, 14, 24.	3.7	25
117	Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. <i>British Journal of Cancer</i> , 1996, 74, 1423-1426.	6.4	24
118	A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis. <i>Gynecologic Oncology</i> , 2004, 92, 936-940.	1.4	24
119	Anticancer activity and mode of action of titanocene C. <i>Investigational New Drugs</i> , 2011, 29, 607-614.	2.6	24
120	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	1.8	23
121	Estrogen Does Not Induce the Calcium-Dependent Nitric Oxide Synthase in Cultured Human Uterine Endothelial and Myometrial Smooth Muscle Cells. <i>Journal of Vascular Research</i> , 1997, 34, 281-288.	1.4	22
122	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. , 1997, 74, 322-325.		22
123	In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. <i>Metal-Based Drugs</i> , 2009, 2009, 1-11.	3.8	22
124	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	1.4	22
125	Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. <i>Cancer Letters</i> , 2015, 362, 218-228.	7.2	22
126	Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. <i>BMC Cancer</i> , 2010, 10, 682.	2.6	21



#	ARTICLE	IF	CITATIONS
127	Association of TAP Gene Polymorphisms and Risk of Cervical Intraepithelial Neoplasia. <i>Disease Markers</i> , 2013, 35, 79-84.	1.3	21
128	Polymorphisms of the Interleukin-1 Gene Cluster and Ovarian Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 386-390.	1.7	20
129	PARP inhibition causes premature loss of cohesion in cancer cells. <i>Oncotarget</i> , 2017, 8, 103931-103951.	1.8	20
130	HER-2 oncogene amplification and overall survival of breast carcinoma patients. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1990, 26, 946-949.	0.7	19
131	Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 514-518.	1.4	19
132	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016, 17, 643.	2.8	19
133	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 537-560.	4.1	19
134	Loss of heterozygosity (LOH) atp53 is correlated with LOH atBRCA1 andBRCA2 in various human malignant tumors. <i>International Journal of Cancer</i> , 2000, 88, 319-322.	5.1	18
135	Genetic alterations in endometrial hyperplasia and cancer. <i>Cancer Letters</i> , 2002, 175, 205-211.	7.2	18
136	HIF1 $\alpha$ ; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer &ndash; a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014, 7, 1563.	2.0	18
137	Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors. <i>Tumor Biology</i> , 2016, 37, 12079-12087.	1.8	18
138	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698.	2.5	18
139	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. <i>Analytical Chemistry</i> , 2018, 90, 13273-13279.	6.5	18
140	Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. <i>Anti-Cancer Drugs</i> , 2009, 20, 559-572.	1.4	17
141	Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines. <i>Cancers</i> , 2019, 11, 114.	3.7	17
142	Association of C-reactive protein (CRP) gene polymorphisms, serum CRP levels and cervical cancer prognosis. <i>Anticancer Research</i> , 2011, 31, 2259-64.	1.1	17
143	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003, 10, 1025.	2.6	16
144	The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer &acirc; a multicenter study. <i>BMC Cancer</i> , 2009, 9, 78.	2.6	16

#	ARTICLE	IF	CITATIONS
145	Relaxin and gonadal steroid receptors in uterosacral ligaments of women with and without pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2012, 23, 495-500.	1.4	16
146	Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 257-263.	2.5	15
147	Biochip for K-ras Mutation Screening in Ovarian Cancer. <i>Clinical Chemistry</i> , 2005, 51, 784-787.	3.2	15
148	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> , 0, , .	2.6	15
149	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. <i>Oncology Reports</i> , 2004, 11, 1281-6.	2.6	14
150	A differential PCR system for the determination of CCND1 (Cyclin D1) gene amplification in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 1998, 34, 257-260.	1.5	13
151	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. <i>Oncology Reports</i> , 2005, 13, 375.	2.6	13
152	A Common Interleukin-6 Promoter Polymorphism in Patients With Vulvar Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2005, 12, 617-620.	1.7	13
153	Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium. <i>Molecular Cancer</i> , 2014, 13, 67.	19.2	13
154	Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. <i>International Journal of Oncology</i> , 2003, 22, 51-7.	3.3	13
155	PCR-Mediated Synthesis of Exogenous Competitors for Quantitative RT-PCR. <i>BioTechniques</i> , 1996, 20, 360-362.	1.8	12
156	Expression of MUC1 Splice Variants Correlates with Invasive Growth of Breast Cancer Cell Lines. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 211-219.	2.5	12
157	Expression of the Human &MTC1&MTC1 Gene in Breast Cell Lines and in Breast Cancer Tissues. <i>Oncology Research</i> , 2007, 16, 465-470.	1.5	12
158	Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulate expression of atherogenic LR11 in human coronary artery endothelium. <i>Thrombosis and Haemostasis</i> , 2014, 112, 323-332.	3.4	12
159	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1225.	2.5	12
160	Association of allelic losses on human chromosomal arms 11q and 16q in sporadic breast cancer. , 1996, 69, 307-311.		11
161	Clinical Relevance of TAp73 and p73 Protein Expression in Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 527-531.	1.4	11
162	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patientsâ€ A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Patient satisfaction after breast cancer surgery. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 6-13.	1.9	11
164	Cytosol concentrations of CD44 isoforms in breast cancer tissue. <i>International Journal of Cancer</i> , 1998, 79, 541-545.	5.1	10
165	Simple laboratory score improves the preoperative diagnosis of adnexal mass. <i>Tumor Biology</i> , 2016, 37, 4343-4349.	1.8	10
166	The 811 C/T polymorphism in the 3' untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women. <i>Tumor Biology</i> , 2016, 37, 1009-1015.	1.8	10
167	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
168	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	3.7	10
169	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	3.7	10
170	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. <i>Fertility and Sterility</i> , 2005, 83, 1565-1567.	1.0	9
171	<i>KRAS</i> mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assay. <i>Journal of Clinical Pathology</i> , 2011, 64, 252-256.	2.0	9
172	Determination of Tumor-infiltrating CD8+ Lymphocytes in Human Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 269-276.	1.4	9
173	The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. <i>Anticancer Research</i> , 2007, 27, 1531-5.	1.1	9
174	Detection of p53 Polymorphism at Codon 72 by PCR and Allele-specific Oligonucleotide Hybridization on Microtiter Plates. <i>Clinical Chemistry</i> , 2000, 46, 124-126.	3.2	8
175	Role of p53 in G2/M cell cycle arrest and apoptosis in response to $\gamma$ -irradiation in ovarian carcinoma cell lines. <i>International Journal of Oncology</i> , 2003, 22, 51.	3.3	8
176	HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. <i>Oncology Reports</i> , 2005, 14, 737.	2.6	8
177	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. <i>PLoS ONE</i> , 2017, 12, e0189641.	2.5	8
178	Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. <i>Investigational New Drugs</i> , 2020, 38, 946-955.	2.6	8
179	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. <i>Oncology Reports</i> , 0, , .	2.6	8
180	The prohibitin 3' untranslated region polymorphism in patients with ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 137, 236-239.	1.1	7

#	ARTICLE	IF	CITATIONS
181	New and potential clinical applications of KRAS as a cancer biomarker. Expert Opinion on Medical Diagnostics, 2010, 4, 383-395.	1.6	7
182	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573.	5.1	7
183	Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens. Disease Markers, 2013, 34, 171-177.	1.3	7
184	Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Research, 2007, 27, 1527-30.	1.1	7
185	Loss of Heterozygosity on Chromosome 13q: Suggestion of a Candidate Tumor Suppressor Gene in Sporadic Breast Cancer. Breast Cancer Research and Treatment, 2004, 83, 143-148.	2.5	6
186	Polymorphisms of the Nos3 gene and unexplained late intrauterine fetal death. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 122, 151-155.	1.1	6
187	Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients. Cancer Investigation, 2011, 29, 180-186.	1.3	6
188	Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies. Hypertension in Pregnancy, 2016, 35, 323-329.	1.1	6
189	No association between the human progesterone receptor gene polymorphism PROGINS and risk for ovarian carcinoma in Austrian women. International Journal of Cancer, 2002, 101, 203-203.	5.1	5
190	An Angiotensin-2 gene polymorphism in unexplained intrauterine fetal death: a multi-center study. Journal of Reproductive Immunology, 2005, 65, 47-53.	1.9	5
191	Expression of p16 protein and epidermal growth factor receptor in patients with adenocarcinoma of the uterine cervix: an immunohistochemical analysis. Archives of Gynecology and Obstetrics, 2011, 283, 611-616.	1.7	5
192	Association of HER2 codon 655 polymorphism with ovarian cancer. Tumor Biology, 2016, 37, 7239-7244.	1.8	5
193	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 842.	3.5	5
194	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. Anticancer Research, 2015, 35, 5901-4.	1.1	5
195	Polymorphisms within the Interleukin-1 Gene Family and Unexplained Late Intrauterine Fetal Death: A Multi-center Study. American Journal of Reproductive Immunology, 2005, 53, 132-135.	1.2	4
196	An Interleukin-6 Gene Promoter Polymorphism and Unexplained Late Intrauterine Fetal Death: A Multicenter Study. Journal of the Society for Gynecologic Investigation, 2005, 12, 33-36.	1.7	4
197	The Lack of Laminin-5 as a Prognostic Marker in Low-Grade Cervical Squamous Intraepithelial Lesions. International Journal of Gynecological Pathology, 2007, 26, 89-94.	1.4	4
198	MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer. Oncology Reports, 2012, 27, 673-7.	2.6	4

#	ARTICLE	IF	CITATIONS
199	Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2011, 12, 8530-8538.	4.1	4
200	Gene Expression of Kallikreins in Breast Cancer Cell Lines. <i>Anticancer Research</i> , 2020, 40, 2487-2495.	1.1	4
201	Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. <i>Investigational New Drugs</i> , 2022, 40, 215-223.	2.6	4
202	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22.	1.1	4
203	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	3.7	4
204	Identification of CRASH, a gene deregulated in gynecological tumors. <i>International Journal of Oncology</i> , 2004, 24, 33.	3.3	3
205	Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 663-671.	1.7	3
206	PP057. ENOS14 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia – Analysis of five polymorphisms predisposing to cardiovascular disease in 279 caucasian and 241 african women. <i>Pregnancy Hypertension</i> , 2013, 3, 88.	1.4	3
207	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519.	3.7	3
208	BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. <i>Genes</i> , 2021, 12, 969.	2.4	3
209	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer – A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	3.7	3
210	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. <i>Anticancer Research</i> , 2015, 35, 6667-70.	1.1	3
211	Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. <i>Oncology Reports</i> , 2003, 10, 1551.	2.6	2
212	Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. <i>Oncology Reports</i> , 2003, 10, 1981.	2.6	2
213	Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 107.	2.7	2
214	Comparison of a Prototype Reverse Hybridization Assay and MethyLight for Detection of SFRP2 Promotor Methylation in Fecal DNA. <i>International Journal of Biological Markers</i> , 2017, 32, 467-470.	1.8	2
215	A Miniaturized Ligand Binding Assay for EGFR. <i>International Journal of Proteomics</i> , 2012, 2012, 1-5.	2.0	1
216	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5071-5071.	1.6	1

#	ARTICLE	IF	CITATIONS
217	The prostaglandine E2 transporting organic anion transporting polypeptide OATP4A1: A potential prognostic marker in colorectal cancer?. Journal of Clinical Oncology, 2013, 31, 430-430.	1.6	1
218	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. SSRN Electronic Journal, 0, , .	0.4	1
219	Drug resistance in ovarian cancer: Biomarkers and treatments. Gynecologic Oncology, 2010, 117, 149-151.	1.4	0
220	Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 5034-5034.	1.6	0